Surovatamig not checked
AstraZeneca · AZD0486 · TNB-486
FollowEvery change as it happens, and a Monday email
Trials
11 active
11 in total · 8 in the EU
What this is
- How it works
- An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
- How it’s given
- “Fully human bispecific monoclonal immunoglobulins (Ig) G4 antibody”In the company’s words, NCT07911553 on ClinicalTrials.gov
- Tested for
- Large B-cell Lymphoma (3 trials), B-cell Non-Hodgkin Lymphoma (3 trials), Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV, Untreated Follicular Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL), Primary Membranous Nephropathy, B-cell Acute Lymphoblastic Leukemia (B-ALL) and 9 more
- Main trialPhase 3
- “The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.”In the company’s words, NCT07215585 on ClinicalTrials.gov
- Other names
- AZD0486 · TNB-486
Other drugs for Large B-cell Lymphoma
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- AcalabrutinibAstraZeneca · Phase 3
- EpcoritamabGenmab · Phase 3
- SHR-A1912Hengrui · Phase 3
- TisagenlecleucelNovartis · Phase 3
Coming up11
- 6 Jan 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 21 Apr 2028Phase 2 trial completes · ClinicalTrials.gov
- 19 Jun 2028Phase 1 trial completes · ClinicalTrials.gov
- 27 Jun 2028Phase 1 trial completes · ClinicalTrials.gov
- 4 Jul 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 13 Oct 2028Phase 2 trial completes · ClinicalTrials.gov
- 20 May 2030Phase 1/2 trial completes · ClinicalTrials.gov
- 10 Jun 2030Phase 3 trial completes · ClinicalTrials.gov
- 2 Sep 2030Phase 3 trial completes · ClinicalTrials.gov
- 29 Aug 2031Phase 3 trial completes · ClinicalTrials.gov
- 26 Nov 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 10 Jun 2030 | AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL | |
| Phase 3Not yet recruiting | 2 Sep 2030 | A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5 | |
| Phase 3Recruiting | 29 Aug 2031 | Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) | |
| Phase 3Recruiting | 26 Nov 2031 | A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients | |
| Phase 2Recruiting | 21 Apr 2028 | Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | |
| Phase 2Recruiting | 13 Oct 2028 | A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease | |
| Phase 1/2Recruiting | 6 Jan 2028 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia | |
| Phase 1/2Recruiting | 4 Jul 2028 | A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | |
| Phase 1/2Recruiting | 20 May 2030 | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | |
| Phase 1Active, not recruiting | 19 Jun 2028 | A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma | |
| Phase 1Recruiting | 27 Jun 2028 | Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026